The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11068 malaria professionals are enjoying the free benefits of MalariaWorld today

KAF156

NOT Open Access | Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a Plasmodium falciparum Human Infection Study

October 13, 2021 - 12:43 -- NOT Open Access
Author(s): 
Kublin JG, Murphy SC, Prince WT, et al.
Reference: 
Clin Infect Dis. 2021 Oct 5;73(7):e2407-e2414

KAF156 is a novel antimalarial drug that is active against both liver- and blood-stage Plasmodium parasites, including drug-resistant strains. Here, we investigated the causal prophylactic efficacy of KAF156 in a controlled human malaria infection (CHMI) model.

NOT Open Access | Safety, pharmacokinetics and causal prophylactic efficacy of KAF156 in a Plasmodium falciparum human infection study

July 13, 2020 - 16:22 -- NOT Open Access
Author(s): 
Kublin JG, Murphy SC, Prince WT, et al.
Reference: 
Clin Infect Dis. 2020 Jul 9:ciaa952

KAF156 is a novel antimalarial drug that is active against both liver- and blood- stage Plasmodium parasites, including drug-resistant strains. Here, we investigated the causal prophylactic efficacy of KAF156 in a controlled human malaria infection (CHMI) model.

Subscribe to RSS - KAF156